Treatment of CNS dissemination in systemic lymphoma

Journal of Neuro-Oncology

Volumn 84, Issue 1, 2007, Pages 107-117

  Gleissner, Beate ^a   Chamberlain, M ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Lymphomatousmeningitis; Non Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; LIPOSOME; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THIOTEPA; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DRUG HALF LIFE; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; INCIDENCE; MUCOSA INFLAMMATION; NEUROLOGICAL COMPLICATION; NONHODGKIN LYMPHOMA; STEM CELL TRANSPLANTATION; SYSTEMIC DISEASE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; MENINGITIS;

EID: 34547112312     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9353-z     Document Type: Article

References (67)

1. Bollen EL, Brouwer RE, Hamers S et al (1997) Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 54:854-859
2. Feugier P, Virion JM, Tilly H et al. (2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: Influence of rituximab. Ann Oncol 15:129-133
3. Fonseca R, Habermann TM, Colgan JP et al (2000) Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer 88:154-161
4. Herman TS, Hammond N, Jones SE et al (1979) Involvement of the central nervous system by non-Hodgkin's lymphoma: The Southwest Oncology Group experience. Cancer 43:390-397
5. Hollender A, Kvaloy S, Nome O et al (2002) Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: A risk model. Ann Oncol 13:1099-1107
6. Jahnke K, Thiel E, Martus P et al (2006) Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 85:45-50
7. Zucca E, Conconi A, Mughal TI et al (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20-27
8. Hollender A, Kvaloy S, Lote K et al (2000) Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer 36:1762-1768
9. Recht L, Straus DJ, Cirrincione C et al (1988) Central nervous system metastases from non-Hodgkin's lymphoma: Treatment and prophylaxis. Am J Med 84:425-435
10. Tondini C, Ferreri AJ, Siracusano L et al (1999) Diffuse large-cell lymphoma of the testis. J Clin Oncol 17:2854-2858
11. Hasselblom S, Ridell B, Wedel H et al (2004) Testicular lymphoma-a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol 43:758-765
12. Zinzani PL, Magagnoli M, Frezza G et al (1999) Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna experience. Leuk Lymphoma 32:571-576
13. Tomita N, Kodama F, Kanamori H et al (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 95:576-580
14. Haddy TB, Adde MA, Magrath IT (1991) CNS involvement in small noncleaved-cell lymphoma: Is CNS disease per se a poor prognostic sign? J Clin Oncol 9:1973-1982
15. Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 11:685-690
16. Ersboll J, Schultz HB, Thomsen BL et al (1985) Meningeal involvement in non-Hodgkin's lymphoma: Symptoms, incidence, risk factors and treatment. Scand J Haematol 35:487-496
17. Yoshida S, Morii K, Watanabe M et al (2000) Characteristic features of malignant lymphoma with central nervous system involvement. Surg Neurol 53:163-167
18. Bokstein F, Lossos A, Lossos IS et al (2002) Central nervous system relapse of systemic non-Hodgkin's lymphoma: Results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 43:587-593
19. Johnson GJ, Oken MM, Anderson JR et al (1984) Central nervous system relapse in unfavourable-histology non-Hodgkin's lymphoma: Is prophylaxis indicated? Lancet 2:685-687
20. MacKintosh FR, Colby TV, Podolsky WJ et al (1982) Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases. Cancer 49:586-595
21. Tilly H, Lepage E, Coiffier B et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289
22. Spectre G, Gural A, Amir G et al (2005) Central nervous system involvement in indolent lymphomas. Ann Oncol 16:450-454
23. Anselmo AP, Proia A, Cartoni C et al (1996) Meningeal localization in a patient with Hodgkin's disease. Description of a case and review of the literature. Ann Oncol 7:1071-1075
24. Boehme V, Zeynalova S, Kloess M, Leoffler M, Pfreunschuh M, Schmitz N (2007) Incidence and risk factors of central nervous system recurrence in aggressive NHL - a survey of 1693 patients treated in protocols of the German High-Grade Lymphoma Study Group (DSNHL). Ann Oncol 18(1):149-157
25. Skarin AT, Canellos GP, Rosenthal DS et al (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1:91-98
26. Brachet C, Dufrane JP, Van De Casseye M et al (2000) [Bilateral breast masses]. Rev Med Brux 21:165-169
27. Restrepo A, Raez LE, Byrne GE Jr. et al (1998) Is central nervous system prophylaxis necessary in ocular adnexal lymphoma? Crit Rev Oncog 9:269-273
28. Montserrat E, Bosch F, Lopez-Guillermo A et al (1996) CNS involvement in mantle-cell lymphoma. J Clin Oncol 14:941-944
29. Valdez R, Kroft SH, Ross CW et al (2002) Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol 15:1073-1079
30. Hegde U, Filie A, Little RF et al (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Blood 105:496-502
31. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161-166
32. Anghel G, Petrinato G, Severino A et al (2003) Intravascular B-cell lymphoma: Report of two cases with different clinical presentation but rapid central nervous system involvement. Leuk Lymphoma 44:1353-1359
33. Ferreri AJ, Campo E, Ambrosetti A et al (2004) Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol 15:1215-1221
34. Gokbuget N, Hoelzer D (1998) Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neurooncol 38:167-180
35. Sariban E, Edwards B, Janus C et al (1983) Central nervous system involvement in American Burkitt's lymphoma. J Clin Oncol 1:677-681
36. Perez-Soler R, Smith TL, Cabanillas F (1986) Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 57:971-977
37. Teshima T, Akashi K, Shibuya T et al (1990) Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer 65:327-332
38. van BK, Ha CS, Murphy S et al (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184
39. Glantz MJ, Hoffman JM, Coleman RE et al (1991) Identification of early recurrence of primary central nervous system tumors by (18F)fluorodeoxyglucose positron emission tomography. Ann Neurol 29:347-355
40. Glass JP, Melamed M, Chernik NL et al (1979) Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology 29:1369-1375
41. French CA, Dorfman DM, Shaheen G et al (2000) Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis. Diagn Cytopathol 23:369-374
42. Gleissner B, Siehl J, Korfel A et al (2002) CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 58:390-396
43. Litam JP, Cabanillas F, Smith TL et al (1979) Central nervous system relapse in malignant lymphomas: Risk factors and implications for prophylaxis. Blood 54:1249-1257
44. Glantz MJ, Chamberlain MC, Batchelor T, Eric W, Cavalli F, Shapiro WR (2006) Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. J Clin Oncol 24:1530a
45. Strong JM, Collins JM, Lester C et al (1986) Pharmacokinetics of intraventricular and intravenous N,N′,N"-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 46:6101-6104
46. Grossman SA, Finkelstein DM, Ruckdeschel JC et al (1993) Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 11:561-569
47. Glantz MJ, LaFollette S, Jaeckle KA et al (1999) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17:3110-3116
48. Glantz MJ, Cole BF, Recht L et al (1998) High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 16:1561-1567
49. Cheng AL, Yeh KH, Uen WC et al (1998) Systemic chemotherapy alone for patients with non-acquired immunodeficiency syndrome-related central nervous system lymphoma: A pilot study of the BOMES protocol. Cancer 82:1946-1951
50. Williams CD, Pearce R, Taghipour G et al (1994) Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: Those transplanted with active CNS disease have a poor outcome-a report by the European Bone Marrow Transplant Lymphoma Registry. J Clin Oncol 12:2415-2422
51. Alvarnas JC, Negrin RS, Horning SJ et al (2000) High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:352-358
52. Kasamon YL, Jones RJ, Piantadosi S et al (2005) High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 11:93-100
53. Kim S, Kim DJ, Geyer MA et al (1987) Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res 47:3935-3937
54. Shapiro WR, Schmid M, Glantz M, Miller JJ (2006) A randomized phase III/ IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 24:1528a
55. Rubenstein JL, Combs D, Rosenberg J et al (2003) Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. Blood 101:466-468
56. Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 106:2021-2027
57. Thyss A, Milano G, Deville A et al (1987) Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies. Eur J Cancer Clin Oncol 23:843-847
58. Milano G, Thyss A, Serre DF et al (1990) CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group. Eur J Cancer 26:492-495
59. Millot F, Rubie H, Mazingue F et al (1994) Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate. Leuk Lymphoma 14:141-144
60. Frick J, Ritch PS, Hansen RM et al (1984) Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 2:365-368
61. Delgado J, Canales MA, Garcia B et al (2002) Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature. Am J Hematol 69:127-131
62. McLaughlin P, Velasquez WS, Redman JR et al (1988) Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst 80:1408-1412
63. McMillan A (2005) Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 131:13-21
64. Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 48:2140-2155
65. Kimelberg HK, Kung D, Watson RE et al (1978) Direct administration of methotrexate into the central nervous system of primates. Part 1: Distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection. J Neurosurg 48:883-894
66. Olson JJ, Blakely JO, Grossman SA, Weingart J, Rashid A, Supko J (2006) Differences in the distribution of methotrexate into high grade gliiomas following intravenous administration, as monitored by microdialysis, are associated with blood brain barrier integrity. J Clin Oncol 24(18S):1548a
67. Bleyer WA (1981) Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 65(Suppl 1):89-98